Search
Compugen Ltd
CGENAdd to Watchlist
2.280USD
+0.150+7.04%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
215.58MMarket Cap
6.08P/E TTM
More Details of Compugen Ltd Company
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates. These programs are focused on the development of cancer immunotherapy drugs with potential to harness the immune system to provide treatment solutions in areas of unmet medical needs in various cancer types and patient populations, both as monotherapy and in combination with other drugs. Its pipeline also includes a preclinical stage fusion protein autoimmune product candidate. Its fields of focus are oncology and immunology, with emphasis on its discovery capabilities on immuno-oncology.
Compugen Ltd Info
Ticker SymbolCGEN
Company nameCompugen Ltd
IPO dateAug 01, 2000
CEOOphir (Eran)
Number of employees74
Security typeOrdinary Share
Fiscal year-endAug 01
AddressAzrieli Center
CityHOLON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryIsrael
Postal code5885849
Phone97237658585
Websitehttps://cgen.com/
Ticker SymbolCGEN
IPO dateAug 01, 2000
CEOOphir (Eran)
Company Executives of Compugen Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
29.38K
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
11.41K
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.38K
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
Mr. Sanford (Sandy) Zweifach, CPA
Mr. Sanford (Sandy) Zweifach, CPA
Independent Director
Independent Director
--
--
Mr. Eran Perry
Mr. Eran Perry
Independent Director
Independent Director
--
--
Dr. Oliver Froescheis, Ph.D.
Dr. Oliver Froescheis, Ph.D.
Senior Vice President, Corporate and Business Development
Senior Vice President, Corporate and Business Development
--
--
Dr. Yaron Turpaz, Ph.D.
Dr. Yaron Turpaz, Ph.D.
Senior Vice President, Senior Advisor, Computational Discovery
Senior Vice President, Senior Advisor, Computational Discovery
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Anat Cohen-Dayag, Ph.D.
Dr. Anat Cohen-Dayag, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
75.81K
+25.97%
Dr. Zurit Levine, Ph.D.
Dr. Zurit Levine, Ph.D.
Senior Vice President, Technology Innovation
Senior Vice President, Technology Innovation
29.38K
--
Mr. Gilead Halevy
Mr. Gilead Halevy
Independent Director
Independent Director
11.41K
--
Mr. Eran Ophir
Mr. Eran Ophir
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
11.38K
--
Dr. Kinneret Livnat Savitsky, Ph.D.
Dr. Kinneret Livnat Savitsky, Ph.D.
Independent Director
Independent Director
--
--
Mr. Paul Jai Sekhri
Mr. Paul Jai Sekhri
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
--
--
FAQs
Who are the top five shareholders of Compugen Ltd?
The top five shareholders of Compugen Ltd are: Dr. Anat Cohen-Dayag, Ph.D.
How many institutions hold shares of Compugen Ltd (CGEN)?
As of 2026Q1, 124 institutions hold shares of Compugen Ltd, with a combined market value of approximately 13.75M, accounting for 14.54% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 445223.00.